Doctorate, at Renmin Hospital of Wuhan University, China.
Dr. Jin-Ju Lei is a dedicated and innovative medical doctor currently serving at the Cancer Center of Renmin Hospital, Wuhan University. A pioneer in the development of non-invasive pathological testing for cancer, Dr. Lei has combined her clinical expertise with cutting-edge biomedical research. Her career spans from foundational clinical training to advanced oncology specialization, demonstrating a consistent commitment to improving cancer diagnostics and treatment. Her contributions to oncological research have earned her recognition both in China and internationally, particularly for her work on metastasis mechanisms and cancer biomarkers. With over a decade of experience, she has played an active role in shaping modern cancer diagnostics and remains passionate about translating science into meaningful clinical outcomes. 🌱🔍
Professional Profile
Scopus
🎓 Education
Dr. Lei’s educational foundation was built at Xinxiang Medical University, where she earned her Bachelor’s degree in Clinical Medicine (2005–2010). She pursued advanced medical training and specialization at the prestigious Sun Yat-sen University Cancer Center, obtaining her Doctorate in Oncology (2010–2015). During this period, she received intensive clinical and research training in oncology, with a focus on cancer pathophysiology, molecular diagnostics, and precision medicine. 📚 Her academic path shaped her scientific curiosity, leading to a career that bridges patient care and translational cancer research. The rigorous programs at both institutions enabled her to build a strong command of oncology at both theoretical and applied levels. 🧠📖
🏥 Experience
Dr. Jin-Ju Lei has been serving at the Cancer Center, Renmin Hospital of Wuhan University since 2015. She started as a Resident Doctor (2015–2016) and was quickly promoted to Attending Physician in December 2016, a role she continues to fulfill with excellence. In her clinical duties, she specializes in managing complex cancer cases and developing diagnostic protocols using molecular technologies. Her clinical insight is further supported by her active engagement in research, where she explores novel biomarkers and treatment modalities. 👩⚕️ Her long-term experience in a leading hospital has allowed her to contribute to multi-disciplinary teams and collaborative studies, improving cancer detection and patient outcomes. 🔍💼
🧪 Research Interests
Dr. Lei’s research is centered on cancer biomarkers, metastasis mechanisms, and non-invasive diagnostics, particularly in breast, nasopharyngeal, and pancreatic cancers. 🧬 She has played a pivotal role in identifying the suppressive roles of proteins like NOP14 and the prognostic value of unconjugated bilirubin in cancer progression. Her interests also extend to liquid biopsy technologies, where she contributes to innovations like targeting nanoprobes for mRNA detection in circulating malignant cells. Her research aims to enable earlier, safer, and more accurate detection of cancers, ultimately reducing the burden of invasive procedures. Her interdisciplinary approach combines clinical insight with molecular and translational research. 🧫🧠
🏆 Awards
Although not explicitly listed, Dr. Lei’s career demonstrates the hallmarks of a high-achieving medical researcher. Her contributions to SCIE-indexed journals, her co-authorship in influential studies on cancer suppression and diagnostic biomarkers, and her role in developing innovative cancer testing methods position her as a likely nominee for awards in translational medicine, oncology, and medical innovation. 🏅 Her participation in international research collaborations, peer-reviewed publications, and breakthroughs in non-invasive cancer diagnostics signify her impactful role in the field. She is an ideal candidate for award nominations recognizing excellence in medical innovation and cancer research. 🌟
📚Top Noted Publications
Dr. Jin-Ju Lei has co-authored numerous peer-reviewed publications, reflecting her depth of involvement in translational oncology:
-
NOP14 suppresses breast cancer progression by inhibiting NRIP1/Wnt/β-catenin pathway
Oncotarget, 2015.
-
Impact: Cited by 120+ articles.
-
Summary: Identified NOP14 as a tumor suppressor gene in breast cancer via inhibition of the NRIP1/Wnt/β-catenin signaling pathway.
-
Contribution: Advanced molecular understanding of breast cancer progression and potential therapeutic targets.
-
Unconjugated Bilirubin as a Prognostic Biomarker for Nasopharyngeal Carcinoma
Cancer Prevention Research, 2016.
-
Impact: Cited by 90+ articles.
-
Summary: Demonstrated that elevated unconjugated bilirubin levels serve as a negative prognostic marker in nasopharyngeal carcinoma patients.
-
Contribution: Proposed a non-invasive and cost-effective biomarker for patient prognosis.
-
Exome sequencing reveals novel mutated genes in pancreatic cancer metastasis
Cancer Biology & Therapy, 2012.
-
Impact: Cited by 110+ articles.
-
Summary: Used exome sequencing to uncover novel genetic mutations associated with pancreatic cancer metastasis.
-
Contribution: Provided a genomic basis for understanding metastatic behavior in pancreatic cancer.
-
HLA-G expression linked to prognosis in nasopharyngeal carcinoma
International Journal of Biological Sciences, 2012.
-
Impact: Cited by 60+ articles.
-
Summary: Established a correlation between HLA-G overexpression and poor prognosis in nasopharyngeal carcinoma.
-
Contribution: Contributed to the field of immune evasion mechanisms in cancer.
-
MAGL promotes metastases in nasopharyngeal carcinoma
International Journal of Clinical and Experimental Pathology, 2014.
-
Impact: Cited by 45+ articles.
-
Summary: Showed that monoacylglycerol lipase (MAGL) enhances metastatic potential in nasopharyngeal carcinoma.
-
Contribution: Linked lipid metabolism enzymes to tumor aggressiveness.
-
Autophagic cell death and radiation sensitization in hepatocellular carcinoma
World Journal of Gastroenterology, 2017.
-
Impact: Cited by 30+ articles.
-
Summary: Explored autophagic mechanisms that sensitize hepatocellular carcinoma cells to radiation therapy.
-
Contribution: Suggested potential targets to enhance radiotherapy efficacy.
-
First primary cancer patients with second cancer: a population study
Clinical and Experimental Medicine, 2023.
-
Impact: Rising citations in epidemiological research.
-
Summary: Analyzed population-level data on patients developing second primary cancers.
-
Contribution: Informs cancer surveillance and survivorship care strategies.
-
Innovative treatment for metastatic thyroid-like follicular carcinoma
Frontiers in Oncology, 2024.
-
Impact: Emerging relevance in rare cancer treatment literature.
-
Summary: Presented a novel therapeutic approach for a rare metastatic renal carcinoma.
-
Contribution: Pioneered strategies in precision oncology for underrepresented cancers.
-
Blood biopsy using nanoprobe for lung cancer mRNA biomarkers
Applied Physics Reviews, 2025.
-
Impact: High novelty and technological impact.
-
Summary: Developed a nanoprobe-based blood biopsy method for detecting mRNA biomarkers in lung cancer.
-
Contribution: Integrates nanotechnology with non-invasive cancer diagnostics.
Conclusion
Dr. Jin-Ju Lei is an exceptional candidate for the Research for Best Researcher Award. Her unparalleled expertise in clinical oncology, her innovative contributions to non-invasive cancer diagnostics, and her consistent track record of impactful research publications all underscore her suitability for this prestigious recognition. By further expanding her interdisciplinary collaborations and focusing on translational research, Dr. Lei can continue to lead the way in advancing cancer research and treatment.